Rosalie Nolley
Overview
Explore the profile of Rosalie Nolley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1039
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wen R, Stark J, Marti G, Fan Z, Lyu A, Marques F, et al.
J Clin Invest
. 2024 Oct;
134(24).
PMID: 39436703
Prostate cancer is the second leading cause of male cancer death in the U.S. Current immune checkpoint inhibitor-based immunotherapies have improved survival for many malignancies; however, they have failed to...
2.
Wen R, Qiu Z, Marti G, Peterson E, Marques F, Bermudez A, et al.
J Transl Med
. 2024 Apr;
22(1):383.
PMID: 38659028
Background: Loss of AZGP1 expression is a biomarker associated with progression to castration resistance, development of metastasis, and poor disease-specific survival in prostate cancer. However, high expression of AZGP1 cells...
3.
Eminaga O, Abbas M, Kunder C, Tolkach Y, Han R, Brooks J, et al.
Sci Rep
. 2024 Mar;
14(1):5284.
PMID: 38438436
Prostate cancer pathology plays a crucial role in clinical management but is time-consuming. Artificial intelligence (AI) shows promise in detecting prostate cancer and grading patterns. We tested an AI-based digital...
4.
Liu S, Chai T, Garcia-Marques F, Yin Q, Hsu E, Shen M, et al.
Cell Rep Med
. 2024 Jan;
5(2):101381.
PMID: 38244540
Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis and limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating...
5.
Shen M, Liu S, Toland A, Hsu E, Hartono A, Alabi B, et al.
Br J Cancer
. 2023 Oct;
129(11):1818-1828.
PMID: 37798372
Background: Neuroendocrine phenotype is commonly associated with therapy resistance and poor prognoses in small-cell neuroendocrine cancers (SCNCs), such as neuroendocrine prostate cancer (NEPC) and small-cell lung cancer (SCLC). Expression levels...
6.
Shankar V, Vijayalakshmi K, Nolley R, Sonn G, Kao C, Zhao H, et al.
JCO Precis Oncol
. 2023 Jun;
7:e2200668.
PMID: 37285559
Purpose: Accurately distinguishing renal cell carcinoma (RCC) from normal kidney tissue is critical for identifying positive surgical margins (PSMs) during partial and radical nephrectomy, which remains the primary intervention for...
7.
Piraquive Agudelo J, Upadhyay D, Zhang D, Zhao H, Nolley R, Sun J, et al.
Metabolites
. 2022 Nov;
12(11).
PMID: 36422257
Patient-derived xenografts (PDX) are high-fidelity cancer models typically credentialled by genomics, transcriptomics and proteomics. Characterization of metabolic reprogramming, a hallmark of cancer, is less frequent. Dysregulated metabolism is a key...
8.
Rice M, Kumar V, Tailor D, Garcia-Marques F, Hsu E, Liu S, et al.
Cell Rep Med
. 2022 Mar;
3(2):100502.
PMID: 35243415
Among men, prostate cancer is the second leading cause of cancer-associated mortality, with advanced disease remaining a major clinical challenge. We describe a small molecule, SU086, as a therapeutic strategy...
9.
Garcia-Marques F, Liu S, Totten S, Bermudez A, Tanimoto C, Hsu E, et al.
Prostate
. 2022 Jan;
82(5):605-616.
PMID: 35098564
Background: Distinguishing men with aggressive from indolent prostate cancer is critical to decisions in the management of clinically localized prostate cancer. Molecular signatures of aggressive disease could help men overcome...
10.
Hsu E, Shen M, Aslan M, Liu S, Kumar M, Garcia-Marques F, et al.
Sci Rep
. 2021 Jun;
11(1):13305.
PMID: 34172788
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer that rarely develops de novo in primary tumors and is commonly acquired during the development of treatment resistance. NEPC...